Staley Brod, MD

Staley A. Brod, M.D. has been a Professor of Neurology and the Director of the Division of Neuro-immunology at MCW since 2016. Dr. Brod graduated from Williams College with a degree in Philosophy in 1972 and attended medical school in Belgium at the Rijksuniversitair Centrum Antwerpen and the Universitair Instelling Antwerpen from 1974 to 1979. He obtained his Doctor of Medicine degree from the Medical College of Ohio in 1981. He completed residencies in Internal Medicine and Neurology at the Medical College of Ohio and the Yale-New Haven Medical Center at Yale University Medical School respectively and is board certified in both Internal Medicine and Neurology. He was a Research and Clinical Fellow in Neurology at the Center for Neurologic Disease, Brigham and Women’s Hospital, Harvard Medical School from 1987-1990, an Associate Physician in Neurology at Brigham and Women’s Hospital and an Instructor in Neurology (Medicine) at the Harvard Medical School from 1990-1991.

Following his fellowship training, Dr. Brod became an Assistant Professor of Neurology in Division of Neuroimmunology, University of Texas Southwestern Medical School in Dallas from 1991-93 and subsequently Professor of Neurology in the MS Research Group at the University of Texas Health Science Center at Houston School of Medicine in 2002-2015. He follows 700 patients with multiple sclerosis and has been the principal investigator for clinical trials in multiple sclerosis and type 1 diabetes. Dr Brod is a member of the American Academy of Neurology and the International Society for Interferon and Cytokine Research. Dr. Brod has published over 130 abstracts and papers on the use of ingested type I interferon, ACTH and somatostatin in humans and animal models of autoimmune disease. He was the Barbara Jordan Research Award winner from the National Multiple Sclerosis Society, is a co-investigator of a grant investigating the basic mechanisms of multiple sclerosis funded by the Clayton Foundation, and NIH awardee.

Research Interests: Animal models of auto-immune disease; immunomodulation; oral administration of type 1 interferons and ACTH in multiple sclerosis (MS) and insulin dependent diabetes mellitus (type 1 diabetes), the use of oral somatostatin in autoimmune diseases. The research in his laboratory is directed at understanding the underlying immune abnormalities of human auto-immune disease.